Australia markets open in 9 hours 31 minutes
  • ALL ORDS

    7,282.10
    -45.90 (-0.63%)
     
  • AUD/USD

    0.7782
    +0.0025 (+0.32%)
     
  • ASX 200

    7,017.80
    -47.80 (-0.68%)
     
  • OIL

    63.39
    +0.01 (+0.02%)
     
  • GOLD

    1,777.90
    +7.30 (+0.41%)
     
  • BTC-AUD

    72,115.19
    -832.31 (-1.14%)
     
  • CMC Crypto 200

    1,270.39
    +35.98 (+2.91%)
     

World Oral Mucositis Epidemiology Forecast to 2030 - ResearchAndMarkets.com

·5-min read

The "Oral Mucositis - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

This 'Oral Mucositis (OM) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted OM epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Epidemiology Perspective

The OM epidemiology division provides the insights about historical and current OM patient pool and forecasted trends for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

In the year 2020, the total incident cases of Oral Mucositis were 1,480,453 cases in the 7MM. These cases are expected to grow in the study period 2018-2030.

The disease epidemiology covered in the report provides historical as well as forecasted OM epidemiology segmented as [Total Incident Cases of OM, Grade-specific cases of OM, and Treated cases of OM] scenario of OM in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- OM Epidemiology

Estimates show that the highest incident cases of OM in the 7MM were in the United States, followed by Japan in 2020.

  • The United States, in 2020, accounted for 596,671, OM incident cases, which are expected to grow during the study period, i.e., 2018-2030.

  • In the year 2020, the total incident cases of OM in EU5 were 623,424, which are expected to grow during the study period, i.e., 2018-2030.

  • In the year 2020, the total incident cases of OM in Japan were 260,358, which are expected to grow during the study period, i.e., 2018-2030.

Scope of the Report

  • The OM report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.

  • The OM Report and Model provide an overview of the risk factors and global trends of OM in the seven major markets (7MM: The United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)

  • The report provides insight about the historical and forecasted patient pool of OM in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.

  • The report assesses the disease risk and burden and highlights the unmet needs of OM.

  • The report provides the segmentation of the OM epidemiology by incident cases in the 7MM.

  • The report provides the segmentation of the OM epidemiology by grade-specific cases in the 7MM.

  • The report provides the segmentation of the OM epidemiology by treated cases of OM in the 7MM.

Report Highlights

  • 10-Year Forecast of OM epidemiology

  • 7MM Coverage

  • Total Incident Cases of OM

  • Grade-Specific Cases of OM

  • Treated cases of OM

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to OM?

  • What are the key findings pertaining to the OM epidemiology across the 7MM and which country will have the highest number of patients during the study period (2018-2030)?

  • What would be the total number of patients of OM across the 7MM during the study period (2018-2030)?

  • Among the EU5 countries, which country will have the highest number of patients during the study period (2018-2030)?

  • At what CAGR the patient population is expected to grow in the 7MM during the study period (2018-2030)?

  • What are the various recent and upcoming events which are expected to improve the diagnosis of OM?

Key Topics Covered:

1. Key Insights

2. Executive Summary of Oral Mucositis

3. Oral Mucositis: Patient Share (%) Distribution Overview at a Glance: By Country

4. Epidemiology Methodology

5. Oral Mucositis: Disease Background and Overview

5.1. Introduction

5.1.1. Signs and Symptoms of Oral Mucositis

5.1.2. Risk Factors and Causes of Oral Mucositis

5.1.3. Pathogenesis of Oral Mucositis

5.1.4. Course of Oral Mucositis

5.1.5. Genetics of Oral Mucositis

5.1.6. Complications of Oral Mucositis

6. Diagnosis of Oral Mucositis

6.1.1. Medical history for Oral Mucositis

6.1.2. Grades of Oral Mucositis

7. Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

8. Epidemiology Scenario: 7MM

8.1. Total Incident Cases of Oral Mucositis in the 7MM

8.2. Grade-specific Incident Cases of Oral Mucositis in the 7MM

8.3. Treated Cases of Oral Mucositis in the 7MM

9. The United States Epidemiology

9.1. Total Incident Cases of Oral Mucositis in the United States

9.2. Grade-specific Incident Cases of Oral Mucositis in the United States

9.3. Treated Cases of Oral Mucositis in the United States

10. EU-5 Epidemiology

10.1. Germany

10.1.1. Total Incident Cases of Oral Mucositis in Germany

10.1.2. Grade-specific Incident Cases of Oral Mucositis in Germany

10.1.3. Treated Cases of Oral Mucositis in Germany

10.2. France

10.3. Italy

10.4. Spain

10.5. The United Kingdom

10.6. Japan Epidemiology

11. Unmet Needs

12. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/3ujcuw

View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005523/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900